Common use of Inquiries Clause in Contracts

Inquiries. For contract and other administrative matters: Director of Research Administration The Leukemia & Lymphoma Society 0000 Xxxxxxxxxx Xxxxxx, Xxxxx 000 Xxxxx Xxxxxx, Xxx Xxxx 00000 Email: Xxxxxxxxxxxxxxxx@xxx.xxx For news and publications matters only: LLS Research Communications The Leukemia & Lymphoma Society 0000 Xxxxxxxxxx Xxxxxx, Xxxxx 000 Xxxxx Xxxxxx, XX 00000 Email: XXXXxxxxxxxXxxxxxxxxxxxxx@xxx.xxx Each party acknowledges having read this entire Grant Agreement and with the full power and authority to execute this Agreement, agrees to perform in accordance with the terms and conditions contained herein. Signatures Grantee The Leukemia & Lymphoma Society, Inc Signature: Signature: Print Name: Print Name: Xxx Xxxxxxxxxxx, Ph.D. Title: Title: Chief Scientific Officer Date: Date: Sponsoring Institutional Official LLS Institutional Official Signature: Signature: Print Name: Print Name: Xxxxxxxxx Xxxxxxxx Chief Administrative Officer and Chief Financial Officer Title: Title: Date: Date: Sponsoring Institution Technology Transfer Official Signature: Print Name: Title: Date: ATTACHMENT A‌ THE GRANTEE’S APPLICATION INCLUDED BY REFERENCE ATTACHMENT B THE LEUKEMIA & LYMPHOMA SOCIETY’S PATENT AND INTELLECTUAL PROPERTY AGREEMENT The Leukemia & Lymphoma Society’s (“LLS”) primary purpose in funding scientifically meritorious research is to advance its mission to cure leukemia, lymphoma, Hodgkin’s disease and myeloma, and to improve the quality of life of patients and their families. In this regard, LLS recognizes that certain Inventions (defined below), potentially having public health, scientific, business, or commercial application or value, may be discovered or made in the course of research or development supported with funds furnished by the LLS. LLS desires that such Inventions be effectuated and brought into public use at the earliest possible time, and it recognizes that often this may be best accomplished through patenting and/or licensing of such Inventions. The Parties receiving Grant funds from LLS agree to the following provisions regarding patent and intellectual property rights and licenses resulting from research conducted by Grantee and funded in whole or in part by LLS. This Patent and Intellectual Property Agreement (“IP Agreement”) forms part of the accompanying Grant Agreement between LLS on the one hand, and the Grantee and Sponsoring Institution on the other hand, executed concurrently herewith. Although intended to be consistent with the Grant Agreement, the terms of this IP Agreement supersede any conflicting terms of the Grant Agreement, to the extent any conflicting terms exist.

Inquiries. For contract grant agreement and other administrative matters: Director of Research Administration The Leukemia & Lymphoma Society 0000 Xxxxxxxxxx XxxxxxSociety, Inc. 0 Xxxxxxxxxxxxx Xxxxx, Xxxxx 000 Xxxxx XxxxxxXxx Xxxxx, Xxx Xxxx XX 00000 Email: Xxxxxxxxxxxxxxxx@xxx.xxx For news and publications matters only: LLS Research Communications The Leukemia & Lymphoma Society 0000 Xxxxxxxxxx XxxxxxSociety, Inc. 0 Xxxxxxxxxxxxx Xxxxx, Xxxxx 000 Xxxxx XxxxxxXxx Xxxxx, XX 00000 Email: XXXXxxxxxxxXxxxxxxxxxxxxx@xxx.xxx Each party acknowledges having read this entire Grant Agreement and with the full power and authority to execute this Agreement, agrees to perform in accordance with the terms and conditions contained herein. Signatures Grantee The Leukemia & Lymphoma Society, Inc Inc. The Leukemia & Lymphoma Society, Inc. Signature: Signature: Print Name: Print Name: Xxx Xxxxxxxxxxx, Ph.D. TitlePrint Name: Xxxxxxxxx Xxxxxxxx Title: Chief Scientific Officer Title: Chief Administrative Officer and Chief Financial Officer Date: Date: Sponsoring Institutional Official LLS Institutional Sponsoring Institution Technology Transfer Official Signature: Signature: Print Name: Print Name: Xxxxxxxxx Xxxxxxxx Chief Administrative Officer and Chief Financial Officer Title: Title: Date: Date: The Grantee acknowledges that he or she has read this entire Grant Agreement and agrees with the Sponsoring Institution Technology Transfer Official (but without incurring any personal liability to LLS) to comply with the obligations of the Grantee stated in this Grant Agreement. Signature: Print Name: Title: Date: ATTACHMENT A‌ A THE GRANTEE’S APPLICATION INCLUDED BY REFERENCE ATTACHMENT B THE LEUKEMIA & LYMPHOMA SOCIETY’S PATENT AND INTELLECTUAL PROPERTY AGREEMENT The mission of The Leukemia & Lymphoma Society’s Society (“LLS”) primary purpose in funding scientifically meritorious research is to advance its mission to cure is: Cure leukemia, lymphoma, Hodgkin’s 's disease and myeloma, and to improve the quality of life of patients and their families. In this regard, LLS recognizes that certain Inventions (defined below), potentially having public health, scientific, business, or commercial application or value, may be discovered or made in the course of research or development supported with funds furnished by the LLS. LLS desires that such Inventions be effectuated and brought into public use at the earliest possible time, and it recognizes that often this may be best accomplished through patenting and/or licensing of such Inventions. The Parties receiving Grant funds from LLS agree to the following provisions regarding patent and intellectual property rights and licenses resulting from research conducted by Grantee and funded in whole or in part by LLS. This Patent and Intellectual Property Agreement (“IP Agreement”) forms part of the accompanying Grant Agreement between LLS on the one hand, and the Grantee and Sponsoring Institution on the other handInstitution, executed concurrently herewith. Although intended to be consistent with the Grant Agreement, the terms of this IP Agreement supersede any conflicting terms of the Grant Agreement, to the extent any conflicting terms exist. Capitalized terms used but not defined in this IP Agreement will have the meaning given to such terms in the Agreement.

Inquiries. For contract grant agreement and other administrative matters: Director of Research Administration The Leukemia & Lymphoma Society 0000 Xxxxxxxxxx XxxxxxSociety, Inc. 0 Xxxxxxxxxxxxx Xxxxx, Xxxxx 000 Xxxxx XxxxxxXxx Xxxxx, Xxx Xxxx XX 00000 Email: Xxxxxxxxxxxxxxxx@xxx.xxx For news and publications matters only: LLS Research Communications The Leukemia & Lymphoma Society 0000 Xxxxxxxxxx XxxxxxSociety, Inc. 0 Xxxxxxxxxxxxx Xxxxx, Xxxxx 000 Xxxxx XxxxxxXxx Xxxxx, XX 00000 Email: XXXXxxxxxxxXxxxxxxxxxxxxx@xxx.xxx Each party acknowledges having read this entire Grant Agreement and with the full power and authority to execute this Agreement, agrees to perform in accordance with the terms and conditions contained herein. Signatures Grantee The Leukemia & Lymphoma Society, Inc Inc. LLS Institutional Official Signature: Signature: Print Name: Print Name: Xxx Xxxxxxxxxxx, Ph.D. TitlePrint Name: Xxxxxxxxx Xxxxxxxx Title: Chief Scientific Officer Title: Chief Administrative Officer and Chief Financial Officer Date: Date: Sponsoring Institutional Official LLS Institutional Sponsoring Institution Technology Transfer Official Signature: Signature: Print Name: Print Name: Xxxxxxxxx Xxxxxxxx Chief Administrative Officer and Chief Financial Officer Title: Title: Date: Date: The Grantee acknowledges that he or she has read this entire Grant Agreement and agrees with the Sponsoring Institution Technology Transfer Official (but without incurring any personal liability to LLS) to comply with the obligations of the Grantee stated in this Grant Agreement. Signature: Print Name: Title: Date: ATTACHMENT A‌ A THE GRANTEE’S APPLICATION INCLUDED BY REFERENCE ATTACHMENT B THE LEUKEMIA & LYMPHOMA SOCIETY’S PATENT AND INTELLECTUAL PROPERTY AGREEMENT The mission of The Leukemia & Lymphoma Society’s Society (“LLS”) primary purpose in funding scientifically meritorious research is to advance its mission to cure is: Cure leukemia, lymphoma, Hodgkin’s 's disease and myeloma, and to improve the quality of life of patients and their families. In this regard, LLS recognizes that certain Inventions (defined below), potentially having public health, scientific, business, or commercial application or value, may be discovered or made in the course of research or development supported with funds furnished by the LLS. LLS desires that such Inventions be effectuated and brought into public use at the earliest possible time, and it recognizes that often this may be best accomplished through patenting and/or licensing of such Inventions. The Parties receiving Grant funds funding from LLS agree to the following provisions regarding patent and intellectual property rights and licenses resulting from research conducted by Grantee Investigator (as defined below) and funded in whole or in part by LLS. This Patent and Intellectual Property Agreement (“IP Agreement”) forms part of the accompanying Grant Agreement between LLS on the one hand, and the Grantee and Sponsoring Institution on the other handInstitution, executed concurrently herewith. Although intended to be consistent with the Grant Agreement, the terms of this IP Agreement supersede any conflicting terms of the Grant Agreement, to the extent any conflicting terms exist. Capitalized terms used but not defined in this IP Agreement will have the meaning given to such terms in the Agreement.

Inquiries. For contract grant agreement and other administrative matters: Director of Research Administration The Leukemia & Lymphoma Society 0000 Xxxxxxxxxx XxxxxxSociety, Inc. 0 Xxxxxxxxxxxxx Xxxxx, Xxxxx 000 Xxxxx XxxxxxXxx Xxxxx, Xxx Xxxx XX 00000 Email: Xxxxxxxxxxxxxxxx@xxx.xxx For news and publications matters only: LLS Research Communications The Leukemia & Lymphoma Society 0000 Xxxxxxxxxx XxxxxxSociety, Inc. 0 Xxxxxxxxxxxxx Xxxxx, Xxxxx 000 Xxxxx XxxxxxXxx Xxxxx, XX 00000 Email: XXXXxxxxxxxXxxxxxxxxxxxxx@xxx.xxx Each party acknowledges having read this entire Grant Agreement and with the full power and authority to execute this Agreement, agrees to perform in accordance with the terms and conditions contained herein. Signatures Grantee The Leukemia & Lymphoma Society, Inc Inc. The Leukemia & Lymphoma Society, Inc. Signature: Signature: Print Name: Print Name: Xxx Xxxxxxxxxxx, Ph.D. TitlePrint Name: Xxxxxxxxx Xxxxxxxx Title: Chief Scientific Officer Title: Chief Administrative Officer and Chief Financial Officer Date: Date: Sponsoring Institutional Official LLS Institutional Sponsoring Institution Technology Transfer Official Signature: Signature: Print Name: Print Name: Xxxxxxxxx Xxxxxxxx Chief Administrative Officer and Chief Financial Officer Title: Title: Date: Date: The Grantee acknowledges that he or she has read this entire Grant Agreement and agrees with the Sponsoring Institution Technology Transfer Official (but without incurring any personal liability to LLS) to comply with the obligations of the Grantee stated in this Grant Agreement. Signature: Print Name: Title: Date: ATTACHMENT A‌ THE GRANTEE’S APPLICATION INCLUDED BY REFERENCE ATTACHMENT Attachment A The Grantee’s Application Included by reference Attachment B THE LEUKEMIA & LYMPHOMA SOCIETY’S PATENT AND INTELLECTUAL PROPERTY AGREEMENT The Leukemia & Lymphoma Society’s Patent and Intellectual Property Agreement The mission of The Leukemia & Lymphoma Society (“LLS”) primary purpose in funding scientifically meritorious research is to advance its mission to cure is: Cure leukemia, lymphoma, Hodgkin’s 's disease and myeloma, and to improve the quality of life of patients and their families. In this regard, LLS recognizes that certain Inventions (defined below), potentially having public health, scientific, business, or commercial application or value, may be discovered or made in the course of research or development supported with funds furnished by the LLS. LLS desires that such Inventions be effectuated and brought into public use at the earliest possible time, and it recognizes that often this may be best accomplished through patenting and/or licensing of such Inventions. The Parties receiving Grant funds from LLS agree to the following provisions regarding patent and intellectual property rights and licenses resulting from research conducted by Grantee Xxxxxxx and funded in whole or in part by LLS. This Patent and Intellectual Property Agreement (“IP Agreement”) forms part of the accompanying Grant Agreement between LLS on the one hand, and the Grantee and Sponsoring Institution on the other handInstitution, executed concurrently herewith. Although intended to be consistent with the Grant Agreement, the terms of this IP Agreement supersede any conflicting terms of the Grant Agreement, to the extent any conflicting terms exist. Capitalized terms used but not defined in this IP Agreement will have the meaning given to such terms in the Agreement.

Inquiries. For contract grant agreement and other administrative matters: Director of Research Administration The Leukemia & Lymphoma Society 0000 Xxxxxxxxxx XxxxxxSociety, Inc. 0 Xxxxxxxxxxxxx Xxxxx, Xxxxx 000 Xxxxx XxxxxxXxx Xxxxx, Xxx Xxxx XX 00000 Email: Xxxxxxxxxxxxxxxx@xxx.xxx For news and publications matters only: LLS Research Communications The Leukemia & Lymphoma Society 0000 Xxxxxxxxxx XxxxxxSociety, Inc. 0 Xxxxxxxxxxxxx Xxxxx, Xxxxx 000 Xxxxx XxxxxxXxx Xxxxx, XX 00000 Email: XXXXxxxxxxxXxxxxxxxxxxxxx@xxx.xxx Each party acknowledges having read this entire Grant Agreement and with the full power and authority to execute this Agreement, agrees to perform in accordance with the terms and conditions contained herein. Signatures Grantee The Leukemia & Lymphoma Society, Inc Inc. LLS Institutional Official Signature: Signature: Print Name: Print Name: Xxx Xxxxxxxxxxx, Ph.D. TitlePrint Name: Xxxxxxxxx Xxxxxxxx Title: Chief Scientific Officer Title: Chief Administrative Officer and Chief Financial Officer Date: Date: Sponsoring Institutional Official LLS Institutional Sponsoring Institution Technology Transfer Official Signature: Signature: Print Name: Print Name: Xxxxxxxxx Xxxxxxxx Chief Administrative Officer and Chief Financial Officer Title: Title: Date: Date: The Grantee acknowledges that he or she has read this entire Grant Agreement and agrees with the Sponsoring Institution Technology Transfer Official (but without incurring any personal liability to LLS) to comply with the obligations of the Grantee stated in this Grant Agreement. Signature: Print Name: Title: Date: ATTACHMENT A‌ A THE GRANTEE’S APPLICATION INCLUDED BY REFERENCE ATTACHMENT B THE LEUKEMIA & LYMPHOMA SOCIETY’S PATENT AND INTELLECTUAL PROPERTY AGREEMENT The mission of The Leukemia & Lymphoma Society’s Society (“LLS”) primary purpose in funding scientifically meritorious research is to advance its mission to cure is: Cure leukemia, lymphoma, Hodgkin’s 's disease and myeloma, and to improve the quality of life of patients and their families. In this regard, LLS recognizes that certain Inventions (defined below), potentially having public health, scientific, business, or commercial application or value, may be discovered or made in the course of research or development supported with funds furnished by the LLS. LLS desires that such Inventions be effectuated and brought into public use at the earliest possible time, and it recognizes that often this may be best accomplished through patenting and/or licensing of such Inventions. The Parties receiving Grant funds from LLS agree to the following provisions regarding patent and intellectual property rights and licenses resulting from research conducted by Grantee and funded in whole or in part by LLS. This Patent and Intellectual Property Agreement (“IP Agreement”) forms part of the accompanying Grant Agreement between LLS on the one hand, and the Grantee and Sponsoring Institution on the other handInstitution, executed concurrently herewith. Although intended to be consistent with the Grant Agreement, the terms of this IP Agreement supersede any conflicting terms of the Grant Agreement, to the extent any conflicting terms exist. Capitalized terms used but not defined in this IP Agreement will have the meaning given to such terms in the Agreement.

Inquiries. For contract If you have questions concerning any of the information requested, you should ask your attorney, accountant or other financial advisor. Inquiries regarding subscription procedures should be directed to Xxxxxxx Xxxxxxxxx of Xxxxxxx LLP (xxxxxxx.xxxxxxxxx@xxxxxxx.xxx; (000) 000-0000). You may also contact Xxxxxxxxxx Xxxxxxxxx (xxxxxxxxxx@xxxxxxxxxx.xxx; (000) 000-0000) or the Company’s investor relations department (XXXxxxxxXX@xxxxxxxxxx.xxx) if you have questions about the Company. ​ FOR ALL SUBSCRIBERS ​ ​ ​ [Document #] (for Stone Point use only) ​ Subscription Agreement ​ ________________________________ Name of Subscriber ​ $_________________ Amount of Capital Commitment ​ Stone Point Credit Corporation 00 Xxxxxxxxx Xxxx Greenwich, Connecticut 06830USA ​ Ladies and other administrative mattersGentlemen: Director ​ The undersigned subscriber (the “Subscriber”) understands that Stone Point Credit Corporation, a Delaware corporation (the “Company”), is an externally managed, non-diversified closed-end management investment company that has elected to be treated as a business development company (a “BDC”) under the Investment Company Act of Research Administration The Leukemia & Lymphoma Society 0000 Xxxxxxxxxx Xxxxxx1940, Xxxxx 000 Xxxxx Xxxxxxas amended (the “Investment Company Act”), Xxx Xxxx 00000 Email: Xxxxxxxxxxxxxxxx@xxx.xxx For news as described in the Private Placement Memorandum of the Company (as such document may be amended, amended and publications matters only: LLS Research Communications The Leukemia & Lymphoma Society 0000 Xxxxxxxxxx Xxxxxxrestated or supplemented from time to time and together with any appendices and supplements thereto, Xxxxx 000 Xxxxx Xxxxxx, XX 00000 Email: XXXXxxxxxxxXxxxxxxxxxxxxx@xxx.xxx Each party acknowledges having read this entire Grant Agreement and with the full power and authority “Offering Document”). Subject to execute this Agreement, agrees to perform in accordance with the terms and conditions hereof, and in reliance upon the representations and warranties contained herein. Signatures Grantee The Leukemia & Lymphoma Societyin this subscription agreement (the “Subscription Agreement”), Inc Signature: Signature: Print Name: Print Name: Xxx Xxxxxxxxxxxthe Subscriber irrevocably subscribes for and agrees to purchase shares of common stock, Ph.D. Title: Title: Chief Scientific Officer Date: Date: Sponsoring Institutional Official LLS Institutional Official Signature: Signature: Print Name: Print Name: Xxxxxxxxx Xxxxxxxx Chief Administrative Officer and Chief Financial Officer Title: Title: Date: Date: Sponsoring Institution Technology Transfer Official Signature: Print Name: Title: Date: ATTACHMENT A‌ THE GRANTEE’S APPLICATION INCLUDED BY REFERENCE ATTACHMENT B THE LEUKEMIA & LYMPHOMA SOCIETY’S PATENT AND INTELLECTUAL PROPERTY AGREEMENT The Leukemia & Lymphoma Society’s par value $0.001 per share, of the Company (“LLSShares”) primary purpose ), on the terms and conditions described herein, in funding scientifically meritorious research is to advance its mission to cure leukemiathe Offering Document, lymphoma, Hodgkinin the Company’s disease Amended and myelomaRestated Certificate of Incorporation (the “Certificate of Incorporation”), and to improve the quality of life of patients and their families. In this regard, LLS recognizes that certain Inventions (defined below), potentially having public health, scientific, business, or commercial application or value, may be discovered or made in the course of research or development supported with funds furnished by Company’s Bylaws (the LLS. LLS desires that such Inventions be effectuated “Bylaws” and brought into public use at the earliest possible time, and it recognizes that often this may be best accomplished through patenting and/or licensing of such Inventions. The Parties receiving Grant funds from LLS agree to the following provisions regarding patent and intellectual property rights and licenses resulting from research conducted by Grantee and funded in whole or in part by LLS. This Patent and Intellectual Property Agreement (“IP Agreement”) forms part of the accompanying Grant Agreement between LLS on the one hand, and the Grantee and Sponsoring Institution on the other hand, executed concurrently herewith. Although intended to be consistent together with the Grant AgreementCertificate of Incorporation, the terms of this IP Agreement supersede any conflicting terms of the Grant Agreement, to the extent any conflicting terms exist.“Governing Documents”). ​

Inquiries. For contract and If you have questions concerning any of the information requested, you should ask your attorney, accountant or other administrative matters: Director financial advisor. Inquiries regarding subscription procedures should be directed to Rxxxxxx Xxxxxxxx of Research Administration The Leukemia & Lymphoma Society 0000 Xxxxxxxxxx Dxxxxxx LLP (rxxxxxx.xxxxxxxx@xxxxxxx.xxx; (000) 000-0000). You may also contact Rxxxxx Xxxxx (rxxxxx.xxxxx@xxxxxxx.xxx; (000) 000-0000) or Jxxxx Xxxxxx (jxxxx.xxxxxx@xxxxxxx.xxx; (000) 000-0000) if you have questions about the Company. FOR ALL SUBSCRIBERS Subscription Agreement ________________________________ Name of Subscriber $_________________ Subscription Amount Kxxxxxx Xxxxx Capital Company 200 Xxxxxxx Xxxxxx, Xxxxx 000 Xxxxx Xxxxxx, 0000 Xxx Xxxx 00000 Email: Xxxxxxxxxxxxxxxx@xxx.xxx For news and publications matters only: LLS Research Communications The Leukemia & Lymphoma Society 0000 Xxxxxxxxxx Xxxxxx, Xxxxx 000 Xxxxx XxxxxxXxxx, XX 00000 EmailLadies and Gentlemen: XXXXxxxxxxxXxxxxxxxxxxxxx@xxx.xxx Each party acknowledges having read this entire Grant Agreement The undersigned subscriber (the “Subscriber”) understands that Kxxxxxx Xxxxx Capital Company, a Delaware statutory trust (the “Company”), is an externally managed, non-diversified closed-end management investment company that has elected to be treated as a business development company (a “BDC”) under the Investment Company Act of 1940, as amended (the “Investment Company Act”), as described in the Private Placement Memorandum of the Company (as such document may be amended, amended and restated or supplemented from time to time and together with any appendices and supplements thereto, the full power and authority “Offering Document”). Subject to execute this Agreement, agrees to perform in accordance with the terms and conditions hereof, and in reliance upon the representations and warranties contained herein. Signatures Grantee The Leukemia & Lymphoma Societyin this subscription agreement (the “Subscription Agreement”), Inc Signature: Signature: Print Name: Print Name: Xxx Xxxxxxxxxxxthe Subscriber irrevocably subscribes for and agrees to purchase common shares of beneficial interest, Ph.D. Title: Title: Chief Scientific Officer Date: Date: Sponsoring Institutional Official LLS Institutional Official Signature: Signature: Print Name: Print Name: Xxxxxxxxx Xxxxxxxx Chief Administrative Officer and Chief Financial Officer Title: Title: Date: Date: Sponsoring Institution Technology Transfer Official Signature: Print Name: Title: Date: ATTACHMENT A‌ THE GRANTEE’S APPLICATION INCLUDED BY REFERENCE ATTACHMENT B THE LEUKEMIA & LYMPHOMA SOCIETY’S PATENT AND INTELLECTUAL PROPERTY AGREEMENT The Leukemia & Lymphoma Society’s par value $0.01 per share, of the Company (“LLSShares”) primary purpose ), on the terms and conditions described herein, in funding scientifically meritorious research is the Offering Document, in the Company’s Amended and Restated Agreement and Declaration of Trust (as such document may be further amended, amended and restated or supplemented from time to advance its mission to cure leukemiatime, lymphoma, Hodgkin’s disease and myelomathe “Declaration of Trust”), and to improve the quality of life of patients and their families. In this regard, LLS recognizes that certain Inventions (defined below), potentially having public health, scientific, business, or commercial application or value, may be discovered or made in the course of research or development supported with funds furnished by Company’s Bylaws (the LLS. LLS desires that such Inventions be effectuated “Bylaws” and brought into public use at the earliest possible time, and it recognizes that often this may be best accomplished through patenting and/or licensing of such Inventions. The Parties receiving Grant funds from LLS agree to the following provisions regarding patent and intellectual property rights and licenses resulting from research conducted by Grantee and funded in whole or in part by LLS. This Patent and Intellectual Property Agreement (“IP Agreement”) forms part of the accompanying Grant Agreement between LLS on the one hand, and the Grantee and Sponsoring Institution on the other hand, executed concurrently herewith. Although intended to be consistent together with the Grant AgreementDeclaration of Trust, the terms of this IP Agreement supersede any conflicting terms of the Grant Agreement, to the extent any conflicting terms exist“Governing Documents”).

Inquiries. For contract grant agreement and other administrative matters: Director of Research Administration The Leukemia & Lymphoma Society 0000 Xxxxxxxxxx XxxxxxSociety, Inc. 0 Xxxxxxxxxxxxx Xxxxx, Xxxxx 000 Xxxxx XxxxxxXxx Xxxxx, Xxx Xxxx XX 00000 Email: Xxxxxxxxxxxxxxxx@xxx.xxx For news and publications matters only: LLS Research Communications The Leukemia & Lymphoma Society 0000 Xxxxxxxxxx XxxxxxSociety, Inc. 0 Xxxxxxxxxxxxx Xxxxx, Xxxxx 000 Xxxxx XxxxxxXxx Xxxxx, XX 00000 Email: XXXXxxxxxxxXxxxxxxxxxxxxx@xxx.xxx Each party acknowledges having read this entire Grant Agreement and with the full power and authority to execute this Agreement, agrees to perform in accordance with the terms and conditions contained herein. Signatures Grantee The Leukemia & Lymphoma Society, Inc Inc. The Leukemia & Lymphoma Society, Inc. Signature: Signature: Print Name: Print Name: Xxx Xxxxxxxxxxx, Ph.D. TitlePrint Name: Xxxxxxxxx Xxxxxxxx Title: Chief Scientific Officer Title: Chief Administrative Officer and Chief Financial Officer Date: Date: Sponsoring Institutional Official LLS Institutional Sponsoring Institution Technology Transfer Official Signature: Signature: Print Name: Print Name: Xxxxxxxxx Xxxxxxxx Chief Administrative Officer and Chief Financial Officer Title: Title: Date: Date: The Grantee acknowledges that he or she has read this entire Grant Agreement and agrees with the Sponsoring Institution Technology Transfer Official (but without incurring any personal liability to LLS) to comply with the obligations of the Grantee stated in this Grant Agreement. Signature: Print Name: Title: Date: ATTACHMENT A‌ THE GRANTEE’S APPLICATION INCLUDED BY REFERENCE ATTACHMENT Attachment A The Grantee’s Application Included by reference Attachment B THE LEUKEMIA & LYMPHOMA SOCIETY’S PATENT AND INTELLECTUAL PROPERTY AGREEMENT The Leukemia & Lymphoma Society’s Patent and Intellectual Property Agreement The mission of The Leukemia & Lymphoma Society (“LLS”) primary purpose in funding scientifically meritorious research is to advance its mission to cure is: Cure leukemia, lymphoma, Hodgkin’s 's disease and myeloma, and to improve the quality of life of patients and their families. In this regard, LLS recognizes that certain Inventions (defined below), potentially having public health, scientific, business, or commercial application or value, may be discovered or made in the course of research or development supported with funds furnished by the LLS. LLS desires that such Inventions be effectuated and brought into public use at the earliest possible time, and it recognizes that often this may be best accomplished through patenting and/or licensing of such Inventions. The Parties receiving Grant funds from LLS agree to the following provisions regarding patent and intellectual property rights and licenses resulting from research conducted by Grantee and funded in whole or in part by LLS. This Patent and Intellectual Property Agreement (“IP Agreement”) forms part of the accompanying Grant Agreement between LLS on the one hand, and the Grantee and Sponsoring Institution on the other handInstitution, executed concurrently herewith. Although intended to be consistent with the Grant Agreement, the terms of this IP Agreement supersede any conflicting terms of the Grant Agreement, to the extent any conflicting terms exist. Capitalized terms used but not defined in this IP Agreement will have the meaning given to such terms in the Agreement.

Inquiries. For contract Agreement and other administrative matters: Director of Research Administration The Leukemia & Lymphoma Society 0000 Xxxxxxxxxx XxxxxxSociety, Inc. 0 Xxxxxxxxxxxxx Xxxxx, Xxxxx 000 Xxxxx XxxxxxXxx Xxxxx, Xxx Xxxx XX 00000 Email: Xxxxxxxxxxxxxxxx@xxx.xxx For news and publications matters only: LLS Research Communications The Leukemia & Lymphoma Society 0000 Xxxxxxxxxx XxxxxxSociety, Inc. 0 Xxxxxxxxxxxxx Xxxxx, Xxxxx 000 Xxxxx XxxxxxXxx Xxxxx, XX 00000 Email: XXXXxxxxxxxXxxxxxxxxxxxxx@xxx.xxx Each party acknowledges having read this entire Grant Agreement and with the full power and authority to execute this Agreement, agrees to perform in accordance with the terms and conditions contained herein. Signatures Grantee The Leukemia & Lymphoma Society, Inc Inc. LLS Institutional Official Signature: Signature: Print Name: Print Name: Xxx Xxxxxxxxxxx, Ph.D. TitlePrint Name: Xxxxxxxxx Xxxxxxxx Title: Chief Scientific Officer Title: Chief Administrative Officer and Chief Financial Officer Date: Date: Sponsoring Institutional Official LLS Institutional Sponsoring Institution Technology Transfer Official Signature: Signature: Print Name: Print Name: Xxxxxxxxx Xxxxxxxx Chief Administrative Officer and Chief Financial Officer Title: Title: Date: Date: The Grantee acknowledges that he or she has read this entire Agreement and agrees with the Sponsoring Institution Technology Transfer Official (but without incurring any personal liability to LLS) to comply with the obligations of the Grantee stated in this Agreement. Signature: Print Name: Title: Date: ATTACHMENT A‌ A THE GRANTEE’S APPLICATION INCLUDED BY REFERENCE ATTACHMENT B THE LEUKEMIA & LYMPHOMA SOCIETY’S PATENT AND INTELLECTUAL PROPERTY AGREEMENT The mission of The Leukemia & Lymphoma Society’s Society (“LLS”) primary purpose in funding scientifically meritorious research is to advance its mission to cure is: Cure leukemia, lymphoma, Hodgkin’s 's disease and myeloma, and to improve the quality of life of patients and their families. In this regard, LLS recognizes that certain Inventions (defined below), potentially having public health, scientific, business, or commercial application or value, may be discovered or made in the course of research or development supported with funds furnished by the LLS. LLS desires that such Inventions be effectuated and brought into public use at the earliest possible time, and it recognizes that often this may be best accomplished through patenting and/or licensing of such Inventions. The Parties receiving Grant funds funding from LLS agree to the following provisions regarding patent and intellectual property rights and licenses resulting from research conducted by Grantee Investigator (as defined below) and funded in whole or in part by LLS. This Patent and Intellectual Property Agreement (“IP Agreement”) forms part of the accompanying Grant Agreement – New Idea Award between LLS on the one hand, and the Grantee and Sponsoring Institution on the other handInstitution, executed concurrently herewithherewith (“Grant Agreement”). Although intended to be consistent with the Grant Agreement, the terms of this IP Agreement supersede any conflicting terms of the Grant Agreement, to the extent any conflicting terms exist. Capitalized terms used but not defined in this IP Agreement will have the meaning given to such terms in the Grant Agreement.

Inquiries. For contract grant agreement and other administrative matters: Director of Research Administration The Leukemia & Lymphoma Society 0000 Xxxxxxxxxx XxxxxxSociety, Inc. 0 Xxxxxxxxxxxxx Xxxxx, Xxxxx 000 Xxxxx XxxxxxXxx Xxxxx, Xxx Xxxx XX 00000 Email: Xxxxxxxxxxxxxxxx@xxx.xxx For news and publications matters only: LLS Research Communications The Leukemia & Lymphoma Society 0000 Xxxxxxxxxx XxxxxxSociety, Inc. 0 Xxxxxxxxxxxxx Xxxxx, Xxxxx 000 Xxxxx XxxxxxXxx Xxxxx, XX 00000 Email: XXXXxxxxxxxXxxxxxxxxxxxxx@xxx.xxx Each party acknowledges having read this entire Grant Agreement and with the full power and authority to execute this Agreement, agrees to perform in accordance with the terms and conditions contained herein. Signatures Grantee The Leukemia & Lymphoma Society, Inc Inc. LLS Institutional Official Signature: Signature: Print Name: Print Name: Xxx Xxxxxxxxxxx, Ph.D. TitlePrint Name: Xxxxxxxxx Xxxxxxxx Title: Chief Scientific Officer Title: Chief Administrative Officer and Chief Financial Officer Date: Date: Sponsoring Institutional Official LLS Institutional Sponsoring Institution Technology Transfer Official Signature: Signature: Print Name: Print Name: Xxxxxxxxx Xxxxxxxx Chief Administrative Officer and Chief Financial Officer Title: Title: Date: Date: The Grantee acknowledges that he or she has read this entire Grant Agreement and agrees with the Sponsoring Institution Technology Transfer Official (but without incurring any personal liability to LLS) to comply with the obligations of the Grantee stated in this Grant Agreement. Signature: Print Name: Title: Date: ATTACHMENT A‌ THE GRANTEE’S APPLICATION INCLUDED BY REFERENCE ATTACHMENT Attachment A The Grantee’s Application Included by reference Attachment B THE LEUKEMIA & LYMPHOMA SOCIETY’S PATENT AND INTELLECTUAL PROPERTY AGREEMENT The Leukemia & Lymphoma Society’s Patent and Intellectual Property Agreement The mission of The Leukemia & Lymphoma Society (“LLS”) primary purpose in funding scientifically meritorious research is to advance its mission to cure is: Cure leukemia, lymphoma, Hodgkin’s 's disease and myeloma, and to improve the quality of life of patients and their families. In this regard, LLS recognizes that certain Inventions (defined below), potentially having public health, scientific, business, or commercial application or value, may be discovered or made in the course of research or development supported with funds furnished by the LLS. LLS desires that such Inventions be effectuated and brought into public use at the earliest possible time, and it recognizes that often this may be best accomplished through patenting and/or licensing of such Inventions. The Parties receiving Grant funds funding from LLS agree to the following provisions regarding patent and intellectual property rights and licenses resulting from research conducted by Grantee Investigator (as defined below) and funded in whole or in part by LLS. This Patent and Intellectual Property Agreement (“IP Agreement”) forms part of the accompanying Grant Agreement between LLS on the one hand, and the Grantee and Sponsoring Institution on the other handInstitution, executed concurrently herewith. Although intended to be consistent with the Grant Agreement, the terms of this IP Agreement supersede any conflicting terms of the Grant Agreement, to the extent any conflicting terms exist. Capitalized terms used but not defined in this IP Agreement will have the meaning given to such terms in the Agreement.

Inquiries. For contract and other administrative matters: Director of Research Administration The Leukemia & Lymphoma Society 0000 Xxxxxxxxxx Xxxxxx, Xxxxx 000 Xxxxx Xxxxxx, Xxx Xxxx 00000 Email: Xxxxxxxxxxxxxxxx@xxx.xxx For news and publications matters only: LLS Research Communications The Leukemia & Lymphoma Society 0000 Xxxxxxxxxx Xxxxxx, Xxxxx 000 Xxxxx Xxxxxx, XX 00000 Email: XXXXxxxxxxxXxxxxxxxxxxxxx@xxx.xxx Each party acknowledges having read this entire Grant Agreement and with the full power and authority to execute this Agreement, agrees to perform in accordance with the terms and conditions contained herein. Signatures Grantee The Leukemia & Lymphoma Society, Inc Signature: Signature: Print Name: Print Name: Xxx Xxxxxxxxxxx, Ph.D. Title: Title: Chief Scientific Officer Date: Date: Sponsoring Institutional Official LLS Institutional Official Signature: Signature: Print Name: Print Name: Xxxxxxxxx Xxxxxxxx Chief Administrative Officer and Chief Financial Officer Title: Title: Date: Date: Sponsoring Institution Technology Transfer Official Signature: Print Name: Title: Date: ATTACHMENT A‌ THE GRANTEE’S APPLICATION INCLUDED BY REFERENCE Included by reference ATTACHMENT B THE LEUKEMIA The Leukemia & LYMPHOMA SOCIETY’S PATENT AND INTELLECTUAL PROPERTY AGREEMENT Lymphoma Society’s Patent and Intellectual Property Agreement The Leukemia & Lymphoma Society’s (“LLS”) primary purpose in funding scientifically meritorious research is to advance its mission to cure leukemia, lymphoma, Hodgkin’s disease and myeloma, and to improve the quality of life of patients and their families. In this regard, LLS recognizes that certain Inventions (defined below), potentially having public health, scientific, business, or commercial application or value, may be discovered or made in the course of research or development supported with funds furnished by the LLS. LLS desires that such Inventions be effectuated and brought into public use at the earliest possible time, and it recognizes that often this may be best accomplished through patenting and/or licensing of such Inventions. The Parties receiving Grant funds from LLS agree to the following provisions regarding patent and intellectual property rights and licenses resulting from research conducted by Grantee and funded in whole or in part by LLS. This Patent and Intellectual Property Agreement (“IP Agreement”) forms part of the accompanying Grant Agreement between LLS on the one hand, and the Grantee and Sponsoring Institution on the other hand, executed concurrently herewith. Although intended to be consistent with the Grant Agreement, the terms of this IP Agreement supersede any conflicting terms of the Grant Agreement, to the extent any conflicting terms exist.

Inquiries. For contract grant agreement and other administrative matters: Director of Research Administration The Leukemia & Lymphoma Society 0000 Xxxxxxxxxx XxxxxxSociety, Inc. 0 Xxxxxxxxxxxxx Xxxxx Xxxxx 000 Xxxxx XxxxxxXxx Xxxxx, Xxx Xxxx XX 00000 Email: Xxxxxxxxxxxxxxxx@xxx.xxx For news and publications matters only: LLS Research Communications The Leukemia & Lymphoma Society 0000 Xxxxxxxxxx XxxxxxSociety, Inc. 0 Xxxxxxxxxxxxx Xxxxx Xxxxx 000 Xxxxx XxxxxxXxx Xxxxx, XX 00000 Email: XXXXxxxxxxxXxxxxxxxxxxxxx@xxx.xxx SIGNATURE PAGE FOLLOWS Each party acknowledges having read this entire Grant Agreement and with the full power and authority to execute this Agreement, agrees to perform in accordance with the terms and conditions contained herein. Signatures Grantee The Leukemia & Lymphoma Society, Inc Inc. The Leukemia & Lymphoma Society, Inc. Signature: Signature: Print Name: Print Name: Xxx Xxxxxxxxxxx, Ph.D. TitlePrint Name: Xxxxxxxxx Xxxxxxxx Title: Chief Scientific Officer Title: Chief Administrative Officer and Chief Financial Officer Date: Date: Sponsoring Institutional Official LLS Institutional Sponsoring Institution Technology Transfer Official Signature: Signature: Print Name: Print Name: Xxxxxxxxx Xxxxxxxx Chief Administrative Officer and Chief Financial Officer Title: Title: Date: Date: The Grantee acknowledges that he or she has read this entire Grant Agreement and agrees with the Sponsoring Institution Technology Transfer Official (but without incurring any personal liability to LLS) to comply with the obligations of the Grantee stated in this Grant Agreement. Signature: Print Name: Title: Date: ATTACHMENT A‌ A THE GRANTEE’S APPLICATION INCLUDED BY REFERENCE ATTACHMENT B THE LEUKEMIA & LYMPHOMA SOCIETY’S PATENT AND INTELLECTUAL PROPERTY AGREEMENT SPECIFIC TO AWARDEES OF MEDICINAL CHEMISTRY GRANTS THROUGH THE REQUEST FOR PROPOSAL The mission of Leukemia & Lymphoma Society’s Society (“LLS”) primary purpose in funding scientifically meritorious research is to advance its mission to cure leukemia, lymphoma, Hodgkin’s disease and myeloma, and to improve the quality of life of patients and their families. In this regard, LLS recognizes that certain Inventions (defined below), potentially having public health, scientific, business, or commercial application or value, may be discovered or made in the course of research or development supported with funds furnished by the LLS. LLS desires that such Inventions be effectuated and brought into public use at the earliest possible time, and it recognizes that often this may be best accomplished through patenting and/or licensing of such Inventions. The Parties parties receiving Grant funds from LLS agree funding through LLS's Screen to Lead Program agrees to the following provisions regarding patent and intellectual property rights and licenses resulting from research conducted by Grantee and Investigator (as defined below), whether funded in whole or in part by LLS. This Patent and Intellectual Property Agreement (“IP Agreement”) forms part of the accompanying Grant Agreement between LLS on the one hand, and the Grantee and Sponsoring Institution on the other handInstitution, executed concurrently herewith. Although intended to be consistent with the Grant Agreement, the terms of this IP Agreement supersede any conflicting terms of the Grant Agreement, to the extent any conflicting terms exist. Capitalized terms used but not defined in this IP Agreement will have the meaning given to such terms in the Agreement.